MEBAll clinical trials have been a success, submitting their de novo application to the FDA later this year. That should tell you everytjing you need to know how dirt cheap this stock is. Not a day trade.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
